atenolol + hydrochlorothiazide + amlodipine

Atenolol + hydrochlorothiazide + amlodipine is a combination drug comprised of **atenolol** (a beta-1 adrenergic receptor antagonist), **hydrochlorothiazide** (a thiazide diuretic), and **amlodipine** (a calcium channel blocker). This triple-therapy combination is designed for the treatment of **hypertension** (high blood pressure) in patients who require more than two antihypertensive agents for adequate control. - **Atenolol** works by selectively blocking beta-1 adrenergic receptors, decreasing heart rate and myocardial contractility, thereby reducing cardiac output and lowering blood pressure. - **Hydrochlorothiazide** inhibits sodium reabsorption at the distal convoluted tubules in the kidneys, increasing the excretion of sodium and water, which lowers blood volume and thus blood pressure. - **Amlodipine** inhibits L-type calcium channels in vascular smooth muscle and myocardium, causing vasodilation, which decreases peripheral resistance and lowers blood pressure. This fixed-dose combination is not commonly marketed under a unique brand name in most jurisdictions and may be compounded or provided as separate agents. Primary indication is **hypertension**.

Other names

atenolol + hydrochlorothiazide + amlodipine